Browse By: Country ι Category ι Publisher ι Tag

Hepatitis Market Research Reports

Hepatitis C Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
Hepatitis is defined as the inflammation of the liver due to an infection by a virus or other causative organism or toxin. Hepatitis C on the other hand, is primarily as a result of the infection by hepatitis C virus (HCV). With a cure rate between 50%-80%, and no commercially available vaccine as of yet, hepatitis C is considered a deadly disease with a moderate to high infection rate. It is the leading cause for liver transplantation in the U.K and North America.  The transmission of this virus in a majority occurs from injectables drug abuse, as the virus can only be transmitted via blood-to-blood contact. The secondary transmission factors include tattooing, sexual contact, healthcare (blood transfusion, organ transplant) mishaps, and other rare unknown cases. HIV infected indi
Published Date: Apr 2025
Published By: Transparency Market Research

Price: $4795
Hepatitis Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
Hepatitis is a medical condition characterized by inflammation of the liver which often leads to other complications such as jaundice, anorexia, liver failure and cirrhosis. Hepatitis is generally of two types- acute when it lasts for less than six months and chronic when it lasts for longer period. It can be caused by a group of viruses called as hepatitis viruses which include groups A, B, C, D, and E. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization. Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two mont
Published Date: Nov 2020
Published By: Transparency Market Research

Price: $4795
Steatohepatitis-Pipeline Insights, 2014
The Report will be Dispatched in 3 Working Days.  DelveInsights, Steatohepatitis-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Steatohepatitis. This report provides information on the therapeutic development based on the Steatohepatitis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the produ
Published Date: Aug 2014
Published By: DelveInsight

Price: $1250
Non-Alcoholic Steatohepatitis-Pipeline Insights, 2014
The Report will be Dispatched in 3 Working Days.  DelveInsights, Non-Alcoholic Steatohepatitis-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Non-Alcoholic Steatohepatitis. This report provides information on the therapeutic development based on the Non-Alcoholic Steatohepatitis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved i
Published Date: Aug 2014
Published By: DelveInsight

Price: $1250
Hepatitis A-Pipeline Insights, 2014
The Report will be Dispatched in 3 Working Days. SUMMARYDelveInsights, Hepatitis A-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Hepatitis A. This report provides information on the therapeutic development based on the Hepatitis A dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products.
Published Date: Aug 2014
Published By: DelveInsight

Price: $1250
Hepatitis D-Pipeline Insights, 2014
The Report will be Dispatched in 3 Working Days. SUMMARYDelveInsights, Hepatitis D-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Hepatitis D. This report provides information on the therapeutic development based on the Hepatitis D dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products.
Published Date: Aug 2014
Published By: DelveInsight

Price: $1250
Hepatitis C Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
The Report will be Dispatched in 3 Working days.  DelveInsights, Hepatitis C- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclus
Published Date: Aug 2014
Published By: DelveInsight

Price: $2000
Hepatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
The Report will be Dispatched in 3 Working days.  DelveInsights, Hepatitis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusiv
Published Date: Aug 2014
Published By: DelveInsight

Price: $2000
Hepatitis C Virus (HCV) Protease Inhibitors -Pipeline Insights, 2014
The Report will be Dispatched in 3 Working Days.  DelveInsight’s,“Hepatitis C Virus (HCV) Protease Inhibitors-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Hepatitis C Virus (HCV) Protease Inhibitors. This report provides information on the therapeutic development based on the Hepatitis C Virus (HCV) Protease Inhibitors dealing with mechanism of action, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug in
Published Date: Aug 2014
Published By: DelveInsight

Price: $1250
Hepatitis B Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
The Report will be Dispatched in 3 Working days.  DelveInsights, Hepatitis B- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclus
Published Date: Aug 2014
Published By: DelveInsight

Price: $2000
Hepatitis B - Pipeline Review, H1 2014
Hepatitis B - Pipeline Review, H1 2014SummaryGlobal Markets Directs, Hepatitis B - Pipeline Review, H1 2014, provides an overview of the Hepatitis Bs therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects.Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
Published Date: May 2014
Published By: Global Markets Direct

Price: $2000
Hepatitis A - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Hepatitis A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis A and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and fe
Published Date: May 2014
Published By: Global Markets Direct

Price: $2000
Alcoholic Hepatitis - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor pres
Published Date: May 2014
Published By: Global Markets Direct

Price: $2000
Hepatitis Drugs Markets in China
China\'s demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China\'s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled.
Published Date: Apr 2014
Published By: Asia Market Information & Development Company

Price: $4000
Global and China Hepatitis B virus core antibody diagnostic kits (enzyme-linked immunosorbent assay) Industry 2014 Market Research Report
The report firstly introduced Hepatitis B virus core antibody diagnostic kits (enzyme-linked immunosorbent assay) basic information included Hepatitis B virus core antibody diagnostic kits (enzyme-linked immunosorbent assay) definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Hepatitis B virus core antibody diagnostic kits (enzyme-linked immunosorbent assay) industry policy and plan, Hepatitis B virus core antibody diagnostic kits (enzyme-linked immunosorbent assay) product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers Hepatitis B virus core antibody di
Published Date: Mar 2014
Published By: QYResearch

Price: $2200
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC fi
Published Date: Mar 2014
Published By: Global Markets Direct

Price: $2000
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update
GlobalData has released its new Opportunity Analyzer report, OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) Opportunity Analysis and Forecasts to 2017 Event-Driven Update. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfits PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharmas FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class. Scope Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management.  Analysis of the current and future market competition in the global NASH therapeutics market.  Pipeline analysis: comprehensive data
Published Date: Mar 2014
Published By: GlobalData

Price: $7995
Global and China Recombinant Hepatitis B Vaccine (Hansenula polymorpha) Industry 2014 Market Research Report
The report firstly introduced Recombinant Hepatitis B Vaccine(Hansenula polymorpha) basic information included Recombinant Hepatitis B Vaccine(Hansenula polymorpha) definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Recombinant Hepatitis B Vaccine(Hansenula polymorpha) industry policy and plan, Recombinant Hepatitis B Vaccine(Hansenula polymorpha) product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers Recombinant Hepatitis B Vaccine(Hansenula polymorpha) capacity production cost price profit production value gross margin etc details information, at the sa
Published Date: Feb 2014
Published By: QYResearch

Price: $2200
Hepatitis C - Pipeline Review, H1 2014
Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2014’, provides an overview of the Hepatitis C’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is bu
Published Date: Feb 2014
Published By: Global Markets Direct

Price: $2500
Global and China Hepatitis A and B Combined Vaccine Industry 2014 Market Research Report
The report firstly introduced Hepatitis A and B Combined Vaccine basic information included Hepatitis A and B Combined Vaccine definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Hepatitis A and B Combined Vaccine industry policy and plan, Hepatitis A and B Combined Vaccine product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers Hepatitis A and B Combined Vaccine capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Hepatitis A and B Combined Vaccine products customers a
Published Date: Feb 2014
Published By: QYResearch

Price: $2200
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast per
Published Date: Jan 2014
Published By: GlobalData

Price: $10995
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape
GBI Research, has released the pharma report – “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being ach
Published Date: Jan 2014
Published By: GBI Research

Price: $3500
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines  Current and Future Players. The report is a vital source of uptodate information with indepth analysis on the companies in the rapidly growing Prophylactic hepatitis B virus vaccines Market. The report identifies and analyses the key companies shaping and driving the global prophylactic hepatitis B virus vaccines market. The report provides insight into the competitive prophylactic hepatitis B virus vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and inhouse analysis by GlobalDatas team of industry experts. Scope Investigation of current and future market competition for prophylactic hepatitis B virus
Published Date: Jan 2014
Published By: GlobalData

Price: $2995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher serocon
Published Date: Jan 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroco
Published Date: Jan 2014
Published By: GlobalData

Price: $6995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher sero
Published Date: Jan 2014
Published By: GlobalData

Price: $4995
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher ser
Published Date: Jan 2014
Published By: GlobalData

Price: $4995
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rat
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion ra
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.Comvax [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant) Vaccine] i
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022SummaryHepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion r
Published Date: Jan 2014
Published By: GlobalData

Price: $3495
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H2, 2013" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and informat
Published Date: Dec 2013
Published By: GlobalData

Price: $2500
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017
GlobalData has released its new report, OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) Opportunity Analysis and Forecasts to 2017. The NASH market is currently deserted and awaits its first NASH-specific therapy. With novel mechanism of action awaiting approval such as: Genfits PPAR agonist, GFT505 and Intercept Pharmaceuticals/Dainippon Sumitomo Pharmas FXR agonist, Obeticholic Acid. These compounds will race to be the first approved therapy thus claiming first in class. Scope Overview of NASH, including epidemiology, etiology, symptoms, diagnosis, pathology and disease management. Analysis of the current and future market competition in the global NASH therapeutics market. Pipeline analysis: comprehensive data split across Phase II/IIb, emerging trends and mecha
Published Date: Sep 2013
Published By: GlobalData

Price: $7995
Hepatitis C - Pipeline Review, H2 2013
Global Markets Directs, \'Hepatitis C Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Hepatitis C Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altere
Published Date: Aug 2013
Published By: Global Markets Direct

Price: $2500
Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2013
Global Markets Directs, \'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. Non-Alcoholic Steatohepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs
Published Date: Aug 2013
Published By: Global Markets Direct

Price: $2000
Hepatitis - Pipeline Review, H2 2013
Global Markets Directs, \'Hepatitis Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. Hepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or altered based
Published Date: Aug 2013
Published By: Global Markets Direct

Price: $2000
EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022
Nonalcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. NASH is becoming increasingly common with the alarming epidemic of obesity. As obesity is a major risk factor for other metabolic syndrome diseases, such as type 2 diabetes and dyslipidemia, the incorporation of weights from the ageand sex-specific prevalence of obesity in each of the 6MM adds granularity to the forecast analysis, which allowed GlobalData epidemiologists to provide a comprehensive forecast of the prevalent cases of NASH in the 6MM. GlobalDatas epidemiological analysis forecasts that prevalent cases of NASH in the 6MM (US,
Published Date: Aug 2013
Published By: GlobalData

Price: $3995
Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide
Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it.  As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been di
Published Date: Jul 2013
Published By: Renub Research

Price: $1290
Hepatitis Partnering 2007-2013
The Hepatitis Partnering 2007-2013 provides understanding and access to the hepatitis partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of hepatitis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors hepatitis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments c
Published Date: Jul 2013
Published By: Current Partnering

Price: $995
Hepatitis A Global Clinical Trials Review, H1, 2013
GlobalData\'s clinical trial report, Hepatitis A Global Clinical Trials Review, H1, 2013\" provides data on the Hepatitis A clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis A. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData\'s team of industry experts. Not
Published Date: Jun 2013
Published By: GlobalData

Price: $2500
Hepatitis D - Pipeline Review, H1 2013
Global Markets Directs, Hepatitis D - Pipeline Review, H1 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis D, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis D.  Hepatitis D - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be remove
Published Date: Jun 2013
Published By: Global Markets Direct

Price: $2000
Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Vaniprevir, formerly MK-7009, is an HCV therapy being developed by Merck. Vaniprevir is a protease inhibitor. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication (Asselah and Marcellin, 2013). Inhibitors of the HCV protease are, therefore, attractive antiviral drugs. Scope Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as
Published Date: May 2013
Published By: GlobalData

Price: $3495
Faldaprevir and BI 207127 (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Faldaprevir is a direct-acting antiviral being developed by the German company BI for the treatment of HCV infection. Faldaprevir, previously referred to as BI 201335 or BI 1335, is an NS3/4A protease inhibitor (PI) that is currently in Phase III development. Scope Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Falda
Published Date: May 2013
Published By: GlobalData

Price: $3495
Simeprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Simeprevir, previously known as TMC435, is an HCV protease inhibitor (PI) being developed by Janssen, Pharmaceuticals, a subsidiary of Johnson & Johnson. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication. Scope Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed informati
Published Date: May 2013
Published By: GlobalData

Price: $3495
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Sofosbuvir, previously known as GS-7977, is an HCV therapy being developed by Gilead, which obtained the rights to the drug through its acquisition of Pharmasset in November of 2011. As an NS5B nucleotide polymerase inhibitor, sofosbuvir exhorts its antiviral activity by mimicking the natural substrate of the viral RNA-dependent RNA polymerase. Scope Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guideli
Published Date: May 2013
Published By: GlobalData

Price: $3495
AbbVies Combination Therapy: ABT-450, ABT-333, and ABT-267 (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. AbbVie is developing an interferon-free HCV regimen that is a combination of the following three or four drugs: ABT-450 is an inhibitor of the HCV protease. This enzyme is required for viral polyprotein processing, which makes the protease essential for HCV replication (Asselah and Marcellin, 2013). Inhibitors of the HCV protease are, therefore, attractive antiviral drugs. ABT-450 is boosted with ritonavir. ABT-267 is an inhibitor of the HCV NS5A protein, which is un
Published Date: May 2013
Published By: GlobalData

Price: $3495
Daclatasvir, Asunaprevir, and Peginterferon Lambda (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Daclatasvir is a DAA being developed by BMS for the treatment of HCV infection. The mechanism of action of daclatasvir involves the inhibition the NS5A protein. NS5A is unique to HCV, and the protein is essential for multiple functions in the viral lifecycle, including HCV RNA replication, despite not having any enzymatic activity. Scope Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well a
Published Date: May 2013
Published By: GlobalData

Price: $3495
Pegasys (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection.  Pegasys is conjugate of interferon alfa-2a, an antiviral drug, and polyethylene glycol (PEG). The compound enhances the innate antiviral immune response through the JAK/STAT signaling pathway, and it also inhibits viral replication directly through an unknown mechanism.
Published Date: May 2013
Published By: GlobalData

Price: $3495
PegIntron (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection.  PegIntron is a conjugate of interferon alfa-2b, an antiviral drug, and polyethylene glycol (PEG). The compound enhances the innate antiviral immune response, and it also inhibits viral replication directly through an unknown mechanism. Schering-Plough launched the drug in t
Published Date: May 2013
Published By: GlobalData

Price: $3495
Copegus and Rebetol (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection.  Ribavirin is a nucleoside analogue with antiviral activity. The drug has direct antiviral activity against many RNA viruses, but its exact mechanism of action is unknown. Ribavirin has been demonstrated to inhibit the polymerase of HCV in a biochemical reaction, and the dru
Published Date: May 2013
Published By: GlobalData

Price: $3495
Incivek (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection.  Incivek is an inhibitor of the HCV NS3/4A protease. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication and an attractive drug target (Asselah and Marcellin, 2013). Vertex discovered telaprevir in collaboration
Published Date: May 2013
Published By: GlobalData

Price: $3495
Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection.  Victrelis is an anti-HCV drug marketed by Merck. Victrelis inhibits the HCV NS3/4A protease by reversibly binding to enzymes active site. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication (Asselah and Marcell
Published Date: May 2013
Published By: GlobalData

Price: $3495
PharmaPoint: Hepatitis C Virus - Current and Future Players
PharmaPoint: Hepatitis C Virus Current and Future Players Summary GlobalData has released its pharma report, PharmaPoint: Hepatitis C Virus Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing HCV Market. The report identifies and analyses the key companies shaping and driving the global HCV market. The report provides insight into the competitive HCV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts. Scope Investigation of current and future market competition for HCV Competitor assessment Coverage of key
Published Date: May 2013
Published By: GlobalData

Price: $2995
PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus - United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus United States Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - France Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus France Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a prot
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus Germany Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - Italy Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus Italy Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus Italy Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - Spain Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus Spain Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus Spain Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor a
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus United Kingdom Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus United Kingdom Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protea
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - Japan Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus Japan Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus Japan Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus - Brazil Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease
Published Date: May 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Hepatitis C Virus - China Drug Forecast and Market Analysis to 2022
PharmaPoint: Hepatitis C Virus China Drug Forecast and Market Analysis Summary GlobalData has released its new Country report, PharmaPoint: Hepatitis C Virus China Drug Forecast and Market Analysis. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roches Pegasys and Mercks PegIntron) and ribavirin (e.g., Roches Copegus and Mercks Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added
Published Date: May 2013
Published By: GlobalData

Price: $4995
Hepatitis B - Pipeline Review, H1 2013
Global Markets Directs, \'Hepatitis B Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis B.  Hepatitis B Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be remove
Published Date: May 2013
Published By: Global Markets Direct

Price: $2000
Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth
The leading business intelligence provider GBI Research has released its latest research report, entitled “Travel Vaccines Market to 2019 – Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth”. The report provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market.  The report analyzes the market for Travel Vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. In addition, it provides overv
Published Date: May 2013
Published By: GBI Research

Price: $3500
Hepatitis C Market - Global Industry Size, Share, Trends, Analysis And Forecasts 2012 - 2018
The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coalitions and agreements to develop effective treatment on hepatitis C virus. In future, the growth of HCV market is expected to come from emerging markets of Asia Pacific, Middle East, and Latin America as these regions are likely to register maximum number of HCV incidences due to increasing HCV drug addicts.  Hepatitis C virus (HCV) spreads through the blood of infected person by the use of shared needles or equipments used to inject drugs. This is a liver infecting virus that causes acut
Published Date: Apr 2013
Published By: Transparency Market Research

Price: $4795
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022SummaryHepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV is an escalating public health problem and burdens an estimated 3% of the worlds population (Trinks et al., 2012). Unlike other acute viral infections that have a rapid onset, HCV infections often persist for decades (CDC, 2013; Tan, 2006).According to the World Health Organization (WHO), approximately 150 million individuals worldwide have been infected with HCV and about 350,000 deaths occur due to HCV-related liver diseases each year (WHO, 2012). HCV transmission in the US is mainly through direct percutaneous exposure to infected blood. HCV in Europe is mainly associated with injection drug use, which accounts for up to 6
Published Date: Mar 2013
Published By: GlobalData

Price: $3995
Hepatitis Pipeline Review, H1 2013
Global Markets Directs, \'Hepatitis Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis.  Hepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed or alt
Published Date: Mar 2013
Published By: Global Markets Direct

Price: $2000
Hepatitis C - Pipeline Review, H1 2013
Global Markets Directs, \'Hepatitis C Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C.  Hepatitis C Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be remove
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2500
Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2013
Global Markets Directs, \'Non-Alcoholic Steatohepatitis Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis.  Non-Alcoholic Steatohepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Mark
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and
Published Date: Jan 2013
Published By: GlobalData

Price: $2500
China Hepatitis B Vaccine Industry 2013 Deep Research Report
This report has firstly introduced Hepatitis B Vaccine definition classification industry chain etc related information. Then introduced Hepatitis B Vaccine manufacturing technology and product specifications, And then summary statistics China major Hepatitis B Vaccine manufacturers 2009-2013 Hepatitis B Vaccine capacity production supply demand shortage and Hepatitis B Vaccine selling price cost gross margin and production value, and also introduced China 8 manufacturers company basic information, 2009-2013 Hepatitis B Vaccine capacity production price cost gross margin production value China market share etc details information.  In the end, this report introduced 10million pieces/year Hepatitis B Vaccine project feasibility analysis and investment return analysis, also give
Published Date: Jan 2013
Published By: QYResearch

Price: $2000
Hepatitis D - Pipeline Review, H2 2012
Global Markets Directs, \'Hepatitis D Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis D, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis D.  Hepatitis D Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be removed
Published Date: Dec 2012
Published By: Global Markets Direct

Price: $2000
Hepatitis B Pipeline Review, H2 2012
Global Markets Directs, \'Hepatitis B Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis B.  Hepatitis B Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the report may be remove
Published Date: Nov 2012
Published By: Global Markets Direct

Price: $2000
Steatohepatitis Pipeline Review, H2 2012
Steatohepatitis Pipeline Review, H2 2012 Global Markets Directs, 'Steatohepatitis Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Steatohepatitis. Steatohepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note
Published Date: Oct 2012
Published By: Global Markets Direct

Price: $2000
Hepatitis C Therapeutics Market to 2018 - Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy
Hepatitis C Therapeutics Market to 2018 Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy GBI Research, the leading business intelligence provider, has released its latest research Hepatitis C Therapeutics Market to 2018 Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy, which provides insights into the global hepatitis C therapeutics market up to 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report examines the global hepatitis C treatment usage patterns, and the geographical distribution of hepatitis C therapeutics and markets across the US
Published Date: Oct 2012
Published By: GBI Research

Price: $3500
Global Hepatitis Drugs Market 2011-2015
TechNavio's analysts forecast the Global Hepatitis Drugs market to grow at a CAGR of 12.42 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in demand for hepatitis drugs in developing countries. The Global Hepatitis Drugs market has also been witnessing an increase in the number of mergers and acquisitions. However, the shortage of hepatitis drugs to meet market demand could pose a challenge to the growth of this market. TechNavio's report, the Global Hepatitis Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis Drugs market landscape and its growth prospects in the
Published Date: Sep 2012
Published By: Technavio

Price: $1500
Analysis of Chinas Hepatitis B Vaccine Industry, 2012-2016
According to the National Serum Epidemiological Survey of Hepatitis B and the Related Diseases, hepatitis B surface antigen carrier rate of 1 to 59 years old group nationwide is 7.18%. Calculated at this data, there are still about 93 million hepatitis B surface antigen carriers in China. In May 2012, (24 Oclock of May 1st to 24 Oclock of May 31st, 2012), there were 113,147 reported morbidity cases and 56 deaths all over China. Over the years, China has promulgated a series of policies on inoculation of hepatitis B vaccination. However, relative to the high carrier rate of hepatitis B patients in China, the supporting power of the national policies is not enough. The above data shows that there are still many problems in the implementation of hepatitis B vaccine policies, and the
Published Date: Sep 2012
Published By: Huidian Research

Price: $1900
Hepatitis - Pipeline Review, H2 2012
Hepatitis Pipeline Review, H2 2012 Global Markets Directs, \'Hepatitis Pipeline Review, H2 2012\', provides an overview of the Hepatitis therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. \'Hepatitis Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain sections in the r
Published Date: Aug 2012
Published By: Global Markets Direct

Price: $2500
Non- Alcoholic Steatohepatitis - Pipeline Review, H2 2012
NonAlcoholic Steatohepatitis Pipeline Review, H2 2012 Global Markets Directs, \'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012\', provides an overview of the Non-Alcoholic Steatohepatitis therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. \'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and
Published Date: Aug 2012
Published By: Global Markets Direct

Price: $2000
Hepatitis C - Pipeline Review, H2 2012
Hepatitis C Pipeline Review, H2 2012 Global Markets Directs, \'Hepatitis C Pipeline Review, H2 2012\', provides an overview of the Hepatitis C therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. \'Hepatitis C Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Note*: Certain secti
Published Date: Aug 2012
Published By: Global Markets Direct

Price: $2500
Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases, primary
Published Date: Jun 2012
Published By: GlobalData

Price: $3995
Hepatitis A Global Clinical Trials Review, H1, 2012
GlobalData's clinical trial report, Hepatitis A Global Clinical Trials Review, H1, 2012" provides data on the Hepatitis A clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis A. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain
Published Date: Jun 2012
Published By: GlobalData

Price: $2500
Global Hepatitis C Drugs Market 2011-2015
TechNavios analysts forecast the Global Hepatitis C Drugs market to grow at a CAGR of 28 percent over the period 20112015. One of the key factors contributing to this market growth is the increasing prevalence of hepatitis C infection. The Global Hepatitis C Drugs market has also been witnessing the shift of treatments from multiple drug therapy to single drug therapy. However, the virus developing resistance to the drugs could pose a challenge to the growth of this market. TechNavios report, the Global Hepatitis C Drugs Market 20112015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis C Drugs market landscape and its growth prospects in th
Published Date: May 2012
Published By: Technavio

Price: $1500
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012
GlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and
Published Date: May 2012
Published By: GlobalData

Price: $1000
Chinese Markets for Hepatitis Drugs
China\'s demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China\'s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled.
Published Date: Apr 2012
Published By: Asia Market Information & Development Company

Price: $4000
Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, Hepatitis B Therapeutics Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-
Published Date: Mar 2012
Published By: GlobalData

Price: $3995
Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016
Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients.  Pegasys, Copegus and Pegintron were the only obtainable drugs in Hepatitis C drug market till May 2011. Pegasys always had more revenue generation in any year compared to Pegintron and is also expected to have higher revenue in future till 2016. However by the end of May 2011, the dynamics of the market has changed after the launch of Incivek and Victrelis. Incivek sale has grown quic
Published Date: Jan 2012
Published By: Renub Research

Price: $975
Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market
GBI Research’s new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.  Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets. This report is
Published Date: Jan 2012
Published By: GBI Research

Price: $3500
Hepatitis B Vaccine - Key patent, SPC, and data exclusivity expiry (44 country coverage)
Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Hepatitis B Vaccine Hepatitis B Vaccine indications: Vaccine against Hepatitis B Hepatitis B Vaccine innovator: GlaxoSmithKline (Engerix B, HBvaxPro); Merck (H-B-Vax II) Examples of information found in this online report include: Includes key patent publications for 44 countries (see list below) Contains SPC protection for every EU state plus patent term extensions in other countries Data exclusivity calculated on a country by country basis Su
Published Date: Dec 2011
Published By: GenericsWeb

Price: $1200
Hepatitis B Vaccine - Comprehensive patent search
Eliminate unnecessary risk with the industry benchmark in comprehensive patent information. Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents, but delivers categorisation and interpretation, all delivered by a convenient online interface.  This Pipeline Developer report covers Hepatitis B Vaccine Hepatitis B Vaccine indications: Vaccine against Hepatitis B Hepatitis B Vaccine innovator: GlaxoSmithKline (Engerix B, HBvaxPro); Merck (H-B-Vax II) Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of w
Published Date: Dec 2011
Published By: GenericsWeb

Price: $8250
Competitor Analysis: Targeted Therapy of Hepatitis C
The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatm
Published Date: Aug 2011
Published By: La Merie Publishing

Price: $772
Global Hepatitis C Virus (HCV) Market An Analysis
d) and chronic (long-lasting) forms of hepatitis C. The incidence rates of HCV vary noticeably, registering the highest rate in the North America. In the past few years, the cases of HCV have increased tremendously in the US, European, Asian and African regions. Comprising of two segments - diagnostic and treatment, the HCV market is driven by various factors like growing world population, obesity, increasing number of HCV incidences globally and rise in number of HCV positive drug addicts. The global market for HCV drugs represents an area of potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technologies, large number of companies are focused on developing innovative HCV drugs. Further, the companies are forming alliances and
Published Date: Aug 2011
Published By: Koncept Analytics

Price: $800
Hepatitis B Global Clinical Trials Review, Q2, 2011
GlobalData's clinical trial report, Hepatitis B Global Clinical Trials Review, Q2, 2011" provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Not
Published Date: Jun 2011
Published By: GlobalData

Price: $1000